Lung cancer is the leading cause of cancer death in the United States and worldwide, accounting for over 150,000 deaths per year in the United States and over 1 million deaths per year world-wide. Non-small cell lung cancer accounts for slightly over 80% of all lung cancer cases. Therefore the development of novel targeted therapeutics for non-small cell lung cancer is of great clinical and public health importance. In recent years, the advent of targeted cancer therapies has led to major advances in the prognosis and survival of cancer patients. Our applicant group has contributed to one of the most dramatic of these advances, the deployment of EGFR inhibitors for patients whose lung cancers bear activating EGFR mutations. This has led to significant advances in treatment of such patients, as demonstrated in this last year by several clinical trials. Nevertheless, as shown by the still-grim mortality statistics, the efforts that lie in front of us far exceed the accomplishments that we and other investigators have achieved to date. The goal of this integrated research Program is to advance the scientific underpinnings of targeted therapies for non-small cell lung cancer. Specifically, we will synthesize, test, and optimize inhibitors of three protein kinases, EGFR, TBK1, and DDR2, for treatment of non-small cell lung cancer. We have chosen these three targets because each one addresses an unmet clinical need in the lung cancer field and because we have an opportunity to generate new approaches for target inhibition.

Public Health Relevance

Lung cancer is the leading cause of cancer death in the United States and worldwide, accounting for over 150,000 deaths per year in the United States and over 1 million deaths per year world-wide. Non-small cell lung cancer accounts for slightly over 80% of all lung cancer cases. Therefore the development of novel targeted therapeutics for non-small cell lung cancer is of great clinical and public health importance. We will synthesize, test, and optimize inhibitors of three protein kinases, EGFR, TBK1, and DDR2, that may serve as novel drugs to treat non-small cell lung cancer.

Agency
National Institute of Health (NIH)
Type
Research Program Projects (P01)
Project #
5P01CA154303-03
Application #
8660042
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02215
Wang, J; Mikse, O; Liao, R G et al. (2015) Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene 34:2167-77
Berger, A H; Imielinski, M; Duke, F et al. (2014) Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene 33:4418-23
Nakayama, Sohei; Sng, Natasha; Carretero, Julian et al. (2014) ?-catenin contributes to lung tumor development induced by EGFR mutations. Cancer Res 74:5891-902
Chen, Zhao; Akbay, Esra; Mikse, Oliver et al. (2014) Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res 20:1204-11
Herter-Sprie, Grit S; Korideck, Houari; Christensen, Camilla L et al. (2014) Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models. Nat Commun 5:5870
Lovly, Christine M; McDonald, Nerina T; Chen, Heidi et al. (2014) Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 20:1027-34
Christensen, Camilla L; Kwiatkowski, Nicholas; Abraham, Brian J et al. (2014) Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 26:909-22
Canning, Peter; Tan, Li; Chu, Kiki et al. (2014) Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors. J Mol Biol 426:2457-70
Chen, Zhao; Fillmore, Christine M; Hammerman, Peter S et al. (2014) Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 14:535-46
Akbay, Esra A; Moslehi, Javid; Christensen, Camilla L et al. (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 28:479-90

Showing the most recent 10 out of 24 publications